We won't be holding @HPJournalClub on Tuesday, November 3 because of the US General Election, but we hope to do something special for that! Stay tuned and please keep on responding to the #MedicareForAll discussion from last night! #HPJC
These bills would fund a @MedicaidGov demonstration project to show the cost-effectiveness of #SCD treatment centers & pairs with the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018” to direct resources. 2/
Commitments to sickle cell disease research are finally generating progress in epidemiology & therapeutics, but lack a mechanism to deliver these therapies & provide necessary preventative care for this debilitating disease! #ConquerSCD@ASH_hematology 3/
https://t.co/wyYoEWonvy
Demonstrating with data what many physicians felt in practice: MIPS doesn’t accurately identify “quality”.
This shouldn’t be a death knell for the principle of incentivizing “value” but speaks to the point that we haven’t gotten to the point where we have defined what we value.
When we distribute health care $ based on how much health care is used, we bias resource allocation away from people who experience barriers to care.
In @JAMANetworkOpen, @wschpero & I look at how this bias manifests in 1 of the largest safety-net hospital subsidy programs.
Medicare and Medicaid allocate ~ $24 billion in subsidies to safety-net hospitals each year.
In a paper out today in @JAMANetworkOpen, @ChatterjeePaula and I show these subsidies are biased against communities of color.
🧵⬇️
1/N
https://t.co/vdYBFpgB9f
Great work by @wschpero and @ChatterjeePaula to uncover and clearly explain the inequity in @CMSGov safety-net hospital subsidies and identify the policy problem (using health care utilization as a proxy for community need for subsidy allocation) that should be changed. #HPJC
Thanks to House @EnergyCommerce for chance to testify on behalf of @AmerMedicalAssn and the profession of medicine on the dangerous chaos patients & physicians facing in many states after Roe reversal. We oppose gov intrusion into exam rooms and criminalization of medical care.
Whether a drug achieves a meaningful benefit to patients (at an acceptable price) is a higher, and more important, bar than for FDA approval. If CMS can succeed in setting such a higher bar, that’s good. That’s the bar we need industry to be shooting for.
I am tired of pharma “patient access” programs.
If you care so much about patient access then stop pricing these meds like they’re rent payments, or cars, or houses.
Updated @AmerMedicalAssn study on competition in health insurance markets is concerning:⬆️consolidation &⬇️choice for patients, particularly in AL, MI, LA, SC, HI, KY, AK, IL, ND, & OK! This⬆️personal insurance costs (even though physician payments⬇️) & limits therapeutic choice!